Landiolol is an investigational drug.
There have been 10 clinical trials for Landiolol.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2019.
The most common disease conditions in clinical trials are Atrial Fibrillation, Shock, Septic, and Tachycardia. The leading clinical trial sponsors are University Hospital, Caen, Medical University of Vienna, and AOP Orphan Pharmaceuticals AG.
There are two hundred and forty-five US patents protecting this investigational drug and two international patents.